SDHB and gastrointestinal stromal tumor: Considering that more than 60% of the patients in our study were heavily pretreated with more than two TKIs, it is noteworthy that patients receiving olverembatinib experienced a clinical benefit rate (CBR) of more than 80% and a median PFS of 25.7 months, compared with 2.9 months in non-SDH-deficient GIST patients.